Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology
Go back to Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology| PUMA BIOTECHNOLOGY, Inc. (NASDAQ: PBYI) | Delayed: 7.92 +0.26 (3.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.66 | 52 Week High | $82.81 | |||
| Open | $7.64 | 52 Week Low | $19.74 | |||
| Day High | $7.98 | P/E | N/A | |||
| Day Low | $7.57 | EPS | $-2.16 | |||
| Volume | 84,447 | |||||
